Human amniotic fluid stem cells have a potential to recover ovarian function in mice with chemotherapy-induced sterility
© Lai et al.; licensee BioMed Central Ltd. 2013
Received: 10 May 2013
Accepted: 2 September 2013
Published: 4 September 2013
Human amniotic fluid cells (hAFCs) may differentiate into multiple cell lineages and thus have a great potential to become a donor cell source for regenerative medicine. The ability of hAFCs to differentiate into germ cell and oocyte-like cells has been previously documented. Herein we report the potential use of hAFCs to help restore follicles in clinical condition involving premature ovarian failure.
Human amniotic fluid was obtained via amniocentesis, yielding a subpopulation of cloned hAFCs that was able to form embryoid bodies (EBs) and differentiate into three embryonic germ layers. Moreover, culture of EBs in medium containing human follicular fluid (HFF) or a germ cell maturation factor cocktail (FAC), expressed germ cells markers such as BLIMP1, STELLA, DAZL, VASA, STRA8, SCP3, SCP1, and GDF9. Furthermore, one cell line was grown from clone cells transfected with lentivirus-GFP and displaying morphological characteristics of mesenchymal cells, had the ability to restore ovarian morphology following cell injection into the ovaries of mice sterilized by intraperitoneal injection of cyclophosphamide and busulphan. Restored ovaries displayed many follicle-enclosed oocytes at all stages of development, but no oocytes or follicles were observed in sterilized mice whose ovaries had been injected with medium only (control). Notably, identification of GFP-labeled cells and immunostaining with anti–human antigen-specific antibodies demonstrated that grafted hAFCs survived and differentiated into granulosa cells which directed oocyte maturation. Furthermore, labeling of ovarian tissue for anti-Müllerian hormone expression, a functional marker of folliculogenesis, was strong in hAFCs-transplanted ovaries but inexistent in negative controls.
These findings highlight the possibility of using human amniotic fluid-derived stem cells in regenerative medicine, in particular in the area of reproductive health.
KeywordsHuman amniotic fluid stem cells Germ cell Folliculogenesis Premature ovarian failure Chemotherapy
Premature ovarian failure (POF) is a defect characterized by the premature depletion of ovarian follicles. Approximately 1% and 0.1% of women under 40 and 30 years of age, respectively, experience POF. While at present about 25% of all forms of POF can be classified as iatrogenic and related to cancer treatment, more than 50% of the cases remain idiopathic [1, 2]. Most women with POF are infertile and suffer unexpected early-onset menopausal symptoms.
Stem cells constitute a unique population possessing self-renewal potential and the ability to differentiate into a specific tissue cell line under defined incubation conditions . Therefore stem cell therapy may potentially provide an avenue to treat women with POF, reproductive aging and/or poor oocyte quality. In this regard embryonic stem (ES) cells have been proposed as a useful model for studying germ cell development. For instance, human ES cells spontaneously expressed germ cell markers during their differentiation into embryoid bodies (EBs) . Moreover, murine and human ES cells differentiated into germ-line cells, underwent meiosis and produced sperm or oocytes, respectively [5, 6]. Regarding the regulation of germ cell development, it was found that DAZL (deleted in azoospermia-like, DAZL) gene expression played a primary role in the differentiation of ES cells into primordial germ cells [7, 8]. Nonetheless, while Dazl expression was required for deriving germ cells from murine ES cells in vitro, this only supported progression through the early stages of meiosis. Thus completion of meiosis required mixing ES cells with minced ovarian tissue and grafting under the kidney capsule of ovariectomized recipient mice to obtain oocytes, albeit at a very low efficiency . Considerable work remains to further define the requirements for in vitro differentiation of ES cells into mature gametes so that these techniques can be clinically applied in regenerative reproductive medicine protocols.
In addition, given the difficulties in growing embryos to obtain human embryonic stem cells, amniotic fluid may be regarded as an alternate source of pluripotent stem cells. Human amniotic fluid contains multiple fetus-derived cell types that possess self-renewal and pluripotency properties. Hence, human amniotic fluid stem cells (AFSCs) have a great potential to become a donor cell source of choice for regenerative medicine . Moreover, human AFSCs display several advantages over ES cells in regards to pluripotency and proliferation rate. For instance, human AFSCs grew extensively in culture and were induced to differentiate into cell types representing different germ layers, that is, into osteogenic, chondrogenic, adipogenic, renal, hematopoietic or neurogenic cell lineages . Furthermore, hAFCs expressed DAZL, suggesting potential ability to differentiate into germ cell lineage cells. Recently, Cheng et al. reported that human amniotic fluid stem cells cultured in medium containing 5% porcine follicular fluid can differentiate into oocyte-like cells .
In this study, we characterized the expression of stem and germ cell markers in undifferentiated hAFCs and observed that germ cell marker expression could be induced in vitro in hAFCs-derived embryoid bodies (EB). Then, to test the functional ability of such cells in vivo, GFP-transfected hAFCs were transplanted into the ovaries of chemically-sterilized mice. Altogether, we highlight a new possibility for using human amniotic fluid cells in regenerative medicine in the area of reproductive health.
Amniotic fluid, follicular fluid and oocyte sample collection
All amniotic fluid cell samples were obtained via amniocentesis performed after the 18th week of pregnancy for routine prenatal diagnosis. The indications were advanced maternal age, a familial or personal history of birth defects, or any foreseen risk of the fetus carrying a chromosomal anomaly or inherited condition. The cytogenetic analyses revealed normal karyotypes for all donors. The mean maternal age was 36 years, with a range of 33–38 years of age, and the mean gestational age was 19 weeks, with a range of 16–22 weeks. Samples of follicular fluid (5 ml) were separately collected from three women (range 29–40 years of age) who were undergoing oocyte pick up for in vitro fertilization and embryo transfer (IVF-ET) to overcome male factor infertility. Ten GV oocytes with fertilization failure were collected from four women (range 32–40 years of age) who were undergoing IVF-ET. This study was carried out with the approval of the Ethics Committee of the International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University, Shanghai, China, and informed consents were obtained from all donors.
Preparation of follicular fluid
Three samples of follicular fluid (5 ml each) were mixed, pooled and centrifuged at 4000 g for 5 min. The supernatant was filtered (0.22 μm pore size) to eliminate contaminating cells potentially present in follicular fluid, aliquoted and stored at −20°C until use. All experiments were performed with the same batch.
Human amniotic fluid cell culture and differentiation
Amniotic fluid samples were centrifuged individually at 4000 × g for 5 minutes at room temperature and the supernatant was discarded. Cellular components were grown in DMEM/F12 medium (Gibco, Grand Island, NY, USA) containing 15% ES-FBS (Gibco, Grand Island, NY, USA), 1% glutamine and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA), supplemented with bFGF (4 ng/ml, Invitrogen, Carlsbad, CA, USA) at 37°C in a 5% CO2 atmosphere. After expansion to confluence (5–7 d), AFSCs formed clones. Then, some clones were used to prepare a single cell suspension by gentle trypsinization. In addition, some clones were picked up and cultured under standard EB media supplemented with 5% human follicular fluid for 7–14 days to promote EB formation. Then, EBs were maintained in differentiation medium which contain germ cell maturation factor cocktail (FAC)  for 7–14 days by replacing half the medium every 3–4 days. The FAC medium consisted of standard EB media supplemented with a germ cell factor cocktail containing: human SCF 100 ng/ml, SDF1 20 ng/ml, bFGF 20 ng/ml, BMP4 50 ng/ml (all R&D Systems, Minneapolis, Minnesota, USA), N-acetylcysteine 1 mg/ml, forskolin 5 mM, retinoic acid 1 mM (all Sigma, St. Louis, Missouri, USA) and CYP26 inhibitor R115866 1 mM (Johnson & Johnson, Brunswick, New Jersey, USA).
RNA extraction and real-time qPCR analysis
Total RNA extraction from samples was performed using the RNeasy Mini Kit (Qiagen, Chataworth, CA, USA). Five hundred ng of total RNA from each sample was used in reverse transcription (RT) using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Real-time RT-qPCR was carried out on cDNA using IQ SYBR Green (Bio-Rad, Hercules, CA, USA) on the Mastercycler ep realplex (Germany). All reactions were performed in a 25-μl volume according to the kit. Primer sequences are listed in Additional file 1: Table S1. Cycling conditions were as follows: 1) for ZPA, ZPC, GDF9, STELLA, STRA8, and DAZL 94°C for 2 min, then 94°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec, 28 cycles, then 72°C for 10 min; for OCT4, CD133, CD117, HLA-DR, BLIMP1, VAZA, SCP1, SCP3, 18 s RNA, 94°C for 2 min, then 94°C for 30 sec, followed by 28 cycles at 53°C for 30 sec and 72°C for 45 sec, finalizing at 72°C for 10 min; and, 2) for NANOG and cMOS, 94°C for 2 min, then 94°C for 30 sec, followed by 28 cycles at 60°C for 30 sec and 72°C for 45 sec, and finalizing at 72°C for 10 min. The amplification efficiency of different genes was determined relative to 18sRNA (∆C t = Ctgene-Ct18sRNA). The quantity of mRNA in each sample was calculated by the comparative (∆∆Ct = ∆Ctgene-∆Ctcontrol) value method. The fold change in gene expression relative to the control was calculated by 2-∆∆Ct . Data were obtained by averaging the results from three independent experiments.
The expression of OCT4 and CD117 was evaluated on both single cell suspensions obtained from hAFCs as well as on cells from EBs. A total of 1 × 106 Cells were suspended in 2% BSA/PBS and labeled with the corresponding antibodies, as follows: 1) mouse anti-human OCT3/4 conjugated with Alexa Fluor 488 (eBioscience, San Diego, CA, USA) and 2) mouse anti-human PE-labeled CD117 (eBioscience, San Diego, CA, USA). Identification of Oct4+ and CD117+ cells was performed using a FC500 flow cytometer (Beckman Coulter, Miami, FL, USA) and analyzed by Beckman Coulter CXP software.
Forty six-week-old C57BL/6 females were prepared as sterilized recipients by intraperitoneal injection of busulfan (30 mg/kg; resuspended in DMSO) and cyclophosphamide (120 mg/kg resuspended in DMSO) once and were observed for 1 week. Five age-matched females injected with DMSO only were used as non-sterilized controls. All animal procedures were approved by the Institutional Animal Care and Use Committee of Shanghai, and were performed in accordance with the National Research Council Guide for Care and Use of Laboratory Animals.
Transfection and transplantation of human amniotic fluid cells
Once hAFCs had grown to a density of 80–90%, lentivirus vector with enhanced green fluorescent proteinlenti-EGFP (a gift from Tianjin Liu ) was added to cultured cells and incubated at 37°C in a 5% CO2 atmosphere for 24 h. Titration of concentrated supernatants was performed by serial dilutions of vector stocks on 1 × 105 Hela cells followed by fluorescence-activated flow cytometry analysis according to the formula: 1 × 105 Hela cell × % EGFP positive cells × 1000/μl virus. Titers of lentiviral vectors were 1 × 108 - 1 × 109 TU/ml. After growing for another 2 days, hAFCs were examined by fluorescence microscopy. The overall cell transfection rate was determined to be greater than 95%. After lentiviral infection for 2 days, hAFCs were washed three times and trypsinized (0.25% trypsin), neutralized in 10% FBS, washed in PBS and resuspended in the culture medium. Recipients were anesthetized by an intraperitoneal injection of pentobarbital sodium (45 mg/kg body weight). Approximately 6 μl of a single-cell suspension, containing 2–5 × 103 cells (n = 30), or 6 μl of culture medium for control (n = 10), was injected into both ovaries of the sterilized recipient. Microinjection of each ovary was performed as previously described according to Zou et al. .
Two months following ovary injection, recipient and control mice were euthanized by cervical dislocation. Ovaries were dissected and fixed in 4% paraformaldehyde (4°C, overnight), dehydrated through a graded series of ethanol, vitrified in xylene, and embedded in paraffin. Six-μm thick sections were fixed for 5 minutes in 10% buffered formalin, after which endogenous peroxidase activity was quenched by incubating the sections in 0.3% hydrogen peroxide in methanol for 30 minutes. Different sections were then incubated in the presence of the following antibodies: mouse anti-human mitochondria (1:300; monoclonal antibody, EMD Millipore, Billerica, Massachusetts, USA); mouse anti-human nuclei (1:100; human nuclei, EMD Millipore, Billerica, Massachusetts, USA); mouse anti-human follicular stimulating hormone receptor (FSHR; 1:100; Abcam, Cambridge, UK); mouse anti-human anti-mullerian hormone (AMH; 1:30 AbD Serotec, Kidlington, Oxford, UK). A peroxidase kit (Vector Laboratories, Burlingame, CA, USA) was used following the manufacturer’s manual. Peroxidase substrate was developed using the DAB (3,39-diaminobenzidine) substrate kit (Vector Laboratories). Slides were counterstained with hematoxylin QS (Vector Laboratories) and were either mounted with low viscosity aqueous mounting medium (Scytek Laboratories, Logan, UT, USA) or dehydrated and mounted with VectaMount Permanent Mounting Medium (Vector Laboratories).
Both individual hAFCs and EBs in suspension were fixed in 4% paraformaldehyde for 15 to 20 min at room temperature, and then washed twice (10 min each) with 1 × PBS. Cells were permeabilized with 0.1% Triton X-100 for 10 min at room temperature, and then washed twice with 1 × PBS. After blocking in 10% skim milk solution for 30 min, cells were incubated with the anti-OCT-4A (rabbit anti-human; 1:200; Santa Cruz, CA, USA), anti-Blimp1 (goat anti-human; 1:200; Santa Cruz, CA, USA), anti-DAZL (goat anti-human; 1:500; Santa Cruz, CA, USA), anti-STELLA (goat anti-human 1:200, Santa Cruz), anti-ZPC (rabbit anti- human; 1:200; Santa Cruz, CA, USA), or anti-SCP3 (rabbit anti-human; 1:800; Abcam, Cambridge, UK) antibodies, for 1 h, at room temperature.
Ovaries from recipient and control mice were fixed with the Tissue-Tek® OCT7™ Compound (Sakura Finetek Middle East, Dubai, United Arab Emirates) and sliced in 5-μm thick sections. Slides were washed twice with PBS and kept in blocking solution for 30 min at room temperature. Slides were then incubated with rabbit polyclonal anti-GFP (1:200; Chemicon, Billerica, Massachusetts, USA) at 4°C, overnight.
Cells or sections were washed three times with 1 × PBS, and probed with FITC-labeled IgG (1:200, Santa Cruz, CA, USA). Fluorescence images were taken using a Leica DMI3000 microscope (Wetzlar, Germany).
Means for relative gene expression were compared by ANOVA using Microsoft Excel software. Statistical significance was set at P < 0.05.
The expression level of stem cell and germ cell markers in undifferentiated human amniotic fluid cells
Then, we examined the expression of germ cell-specific genes in hAFCs as compared with human oocytes. These genes included: B-lymphocyte-induced maturation protein 1 (BLIMP1), STELLA and deleted in azoospermia-like (DAZL), which are known to be expressed in PGCs through later stages of germ cell differentiation; VASA which is known to be expressed during gonocyte formation; stimulated by retinoic acid 8 (STRA8), synaptonemal complex protein 1 and 3 (SCP1, SCP3), moloney sarcoma oncogene (c-MOS), zona pellucida (ZP) gene family (ZPA, ZPC) which are expressed during meiosis; and, growth and differentiation factor 9 (GDF9), which is an adult oocyte-specific marker . Among the pre-meiotic and meiotic germ cell gene markers, STELLA and SCP1, SCP3 were highly expressed in all six hAFCs samples compared with human skin fibroblast cells, whereas the expression of other same-stage markers (DAZL, VASA, GDF9), displayed high variability among samples. Conversely, the expression of STRA8, c-MOS and ZPC was consistently lower in hAFCs samples. Overall, the expression level of the germ cell specific genes was relatively low compared to that in mature oocytes (Figure 1B).
Consistent with the transcriptional profiles, mature oocytes expressed germ cell proteins, including OCT4A, BLIMP1, DAZL, STELLA, ZPC and SCP3 (Figure 1C). However, as evidenced by immunofluorescence, OCT4 protein expression was only detectable in hAFCs (Figure 1D). Altogether, these data suggest that less germ cell gene markers are expressed spontaneously in a subpopulation of hAFCs compared to human mature oocytes.
Cultured hAFC colonies have the ability to differentiate into three embryonic germ cells
These clones were also assayed for pluripotency after resuspension in EB media. We observed hAFC-derived EB formation to be accompanied by induction of the differentiation markers Sox17 (endoderm), muscle actin (mesoderm) and Nextin (ectoderm) (Figure 2E), which is agreement with the report of Valli et al. . This demonstrates that clones obtained from hAFCs harbor high differentiation potential.
Germ cell markers can be induced in cultured hAFCs colones in vitro
In previous studies, the derivation of germ cells relied on the formation of embryoid bodies (EBs) from ES cells. Moreover, differentiation of immature oocytes and sperm from murine and human ES cells in culture has also been reported [4–6]. To determine whether germ cell differentiation could be achieved from hAFCs via EB formation, clones were suspended under EB differentiation medium (Figure 2C). The EB-derived cells were cultured for 1 or 2 weeks in either standard differentiation medium alone or containing a germ cell maturation factor cocktail (FAC) as previously reported . The FAC cocktail comprised antiapoptotic, germ cell specification and meiotic induction factors, including bone morphogenetic protein 4 (BMP4), retinoic acid, CYP26 inhibitor (R115866), stromal cell-derived factor 1 (SDF1), stem cell factor (SCF), and basic fibroblast growth factor (bFGF). We also tested medium supplemented with 5% human follicular fluid (HFF) to investigate its ability to induce the derivation of germ line cells.
Mesenchymal-like hAFCs can restore morphologically chemotherapy-damaged ovaries
Implanted hAFCs infiltrate the chemically-damaged murine ovarian tissue and restore ovarian function
Human-specific antigens, including human nuclei antigen  and human follicle - stimulating hormone receptor (FSHR)  were further used as tracking markers for transplanted hAFCs. To confirm whether GFP-positive cells in recipient ovaries were indeed derived from grafted hAFCs, we performed double-staining with GFP and human specific nuclei antigen in recipient ovarian sections two months following hAFCs transplantation. Results showed that GFP positive staining did co-localize with human anti–nuclei staining in ovarian stroma (Figure 5G-L) or in antral follicles (Figure 5M-R).
Anti-Müllerian hormone (AMH) is a protein expressed by granulosa cells that controls the formation of primary follicles by inhibiting excessive follicular recruitment by FSH. Thus AMH levels are strongly correlated with the size of the follicle pool, and can be used as a marker for ovarian aging, responsiveness and pathophysiology . As shown in Figure 6Ba, AMH expression was strong in granulosa cells of preantral and small antral follicles, and gradually diminished in subsequent stages of follicle development in control ovaries from non-sterilized mice. Conversely, AMH was no longer expressed in ovaries from mice sterilized by chemotherapy (Figure 6Bb) but reappeared in ovarian follicles from sterilized mice when evaluated at 2 months following hAFC transplantation (Figure 6Bc-d).
Altogether, the above presented results suggest that hAFCs integrated into the ovaries of infertile mice and participated in oocyte regeneration. Thus ovarian function can be at least partially restored following hAFC transplantation.
Firstly, we analyzed hAFC samples for the expression of germ cell markers; in agreement to previous reports , we observed a consistently high expression of OCT4 and CD133. However, when we examined additional markers we did not observe expression of genes specific to germ cell differentiation. In this regard, it was reported that hAFCs had the ability to form embryoid bodies (EBs) when cultured under conditions without anti-differentiation factors and without contact to feeder cells. Moreover, the formation of such three-dimensional multicellular aggregates was accompanied by a decrease in stem cell marker expression and by the induction of differentiation into different cell lineages . Hence herein hAFCs kept under a stem cell culture system yielded a high number of clones that when cultured in suspension without anti-differentiation factors, spontaneously formed multicellular EBs and harbored high differentiation potential. Moreover, when we cultured EBs in the presence of germ cell maturation FAC  or 5% HFF, we were able to induce expression of markers consistent with germ cell differentiation.
Indeed, both the germ cell maturation FAC as well as HFF appeared to share factors that could potentially induce the differentiation of human amniotic fluid-derived stem cells into germ cell lineage cells. For instance, HFF, which is produced during folliculogenesis, contains factors that are secreted from granulosa and theca cells, as well as oocytes [33, 34]. Many growth factors and hormones such as activin A, follistatin, SCF, bFGF, AMH and estrogen have been isolated from follicular fluid [35, 36]. In fact, some of these factors, such as SCF and bFGF are also components of the germ cell maturation FAC. The roles of these endocrine–paracrine factors in the regulation of follicular development are well documented [37, 38]. Furthermore, previous research had demonstrated that 5% porcine follicular fluid could induce porcine skin-derived stem cells to form germ cells . Our research further supported these notions in that both HFF and FAC-supplemented media efficiently induced hAFCs to express germ cell-specific genes and hence direct them to enter the germ cell path of differentiation.
While several studies have demonstrated that human ES cells can be induced to differentiate into somatic and germ cell lineages, including germ cell precursors or PGCs [40, 41], germ cell differentiation has been largely limited to the earliest stages. Therefore, ES cell-derived oocyte maturation ultimately fails in vitro [42–44]. Nicholas et al. transplanted ES cell-derived germ cell co-aggregated with wild type newborn ovarian tissue into the kidney capsule of recipient mice and found that the ovarian niche could direct functional maturation of these germ cells . Similarly, isolated female germline stem cells from neonatal mouse ovaries underwent oogenesis and resulted in offspring when transplanted into ovaries of infertile mice . Hence we hypothesized that hAFC-derived stem cells might differentiate into follicles and hence restore folliculogenesis after transplantation to the appropriate niche, that is, into chemically-damaged ovaries. Thus, we established one hAFC line derived from clone cells of one sample, and used for ovarian transplantation.
In order to follow these cells through development, hAFC line were transfected with lentivirus-GFP prior to transplantation. Indeed, GFP-positive cells integrated into the ovarian niche of infertile mice and this was further supported by the identification of human-specific antigen expression, including human nuclei and FSHR in recipient ovaries. Folliculogenesis depends not only on the circulating levels of the gonadotropins but also on the expression of gonadotropin receptors by follicular cells in the ovary. Because human FSHR, which has been localized to granulosa cells of Graafian follicles  was expressed in the ovaries from sterilized mice, this strongly suggested that grafted hAFCs differentiated into granulosa, but not germ cells. Moreover, immunofluorescence detected the expression of human-specific antigens only in the population of follicular supporting cells. Hence, these results strongly support the notion that implanted hAFCs directed follicle formation in the chemically-damaged murine ovary. Notably, increased expression of AMH, a hormone strongly correlated with the size of the follicular pool [28, 45, 46], was marked after hAFCs transplantation in the ovaries of sterilized mice. Conversely, AMH expression is negative in the control groups, further supporting a role of hAFC transplantation in restoring ovarian function in infertile mice.
Interestingly, not all transplanted ovaries from sterilized mice developed GFP(+) or human antigen-positive cells, but we also identified GFP(−) and human antigen-negative follicular growth. These findings suggested that in these cases transplanted hAFCs may have aided in folliculogenesis recovery via indirect trophism on ovarian tissue. This is consistent with studies spanning other organs where improved functionality was observed not due to cell differentiation but to mere supportive effects on existing cells [47, 48].
Worth noting, amniotic fluid-derived cell clones displayed a normal karyotype and no evidence of tumorigenic effect in vivo (Data not shown). In agreement, it was previously reported that hAFCs are genomically stable and harbor neither epigenetic memory nor somatic mutations of already differentiated source cells [11, 29–32]. Moreover, compared to ES cells, there is no ethical and religious concerns associated with hES cells which require the destruction of human embryos . In addition, another promising renewable source of pluripotent cells is constituted by induced pluripotent stem cells (iPSCs), which are obtained from reprogrammed somatic cells using defined factors. However, iPSCs can induce a T-cell-dependent immune response in syngeneic recipients . In this regard, work from others revealed that amniotic fluid-derived cells, hold immunosuppressive properties  making them even more attractive for their potential clinical applications.
This study demonstrated hAFCs obtained from early second trimester stages of fetal development may hold the intrinsic ability to express germ cell markers in vitro and restore folliculogenesis in a germ cell-ablated mouse model. The methods outlined above may provide a platform to elucidate the mechanisms of ovarian function restoring. Altogether, our findings have implications for the future use of stem cells in the treatment of POF and aging-related infertility.
Human amniotic fluid cells
Human follicular fluid
Germ cell maturation factor cocktail
Premature ovarian failure
In vitro fertilization and embryo transfer
Human skin fibroblast cells
Human amnion epithelial cells
Follicle-stimulating hormone receptor
This work was supported by grants from Shanghai Municipal Health Bureau, Shanghai, China (No. XBR2011069), the NSFC (National Natural Science Foundation of China, No. 81070533), the Biomed-X project funds from Shanghai Jiaotong University (No. YG2010MS66) and Shanghai Municipal Council for Science and Technology (No.12431902201).
- Rebar RW: Premature ovarian failure. Obstet Gyneco. 2009, 113: 1355-1363.View Article
- Massin N, Gougeon A, Meduri G: Significance of ovarian histology in the management of patients presenting a premature ovarian failure. Hum Reprod. 2004, 19: 2555-2560. 10.1093/humrep/deh461.View ArticlePubMed
- Cherry AB, Daley GQ: Reprogramming cellular identity for regenerative medicine. Cell. 2012, 148: 1110-1122. 10.1016/j.cell.2012.02.031.PubMed CentralView ArticlePubMed
- Clark AT, Bodnar MS, Fox M: Spontaneous differentiation of germ cells from human embryonic stem cells in vitro. Hum Mol Gene. 2004, 13: 727-739. 10.1093/hmg/ddh088.View Article
- Toyooka Y, Tsunekawa N, Akasu R: Embryonic stem cells can form germ cells in vitro. Proc Natl Acad Sci U S A. 2003, 100: 11457-11462. 10.1073/pnas.1932826100.PubMed CentralView ArticlePubMed
- Hübner K, Fuhrmann G, Christenson LK: Derivation of oocytes from mouse embryonic stem cells. Science. 2003, 300: 1251-1256. 10.1126/science.1083452.View ArticlePubMed
- Kee K, Angeles VT, Flores M, Nguyen HN, Reijo Pera RA, Human DAZL: DAZ and BOULE genes modulate primordial germ-cell and haploid gamete formation. Nature. 2009, 462: 222-225. 10.1038/nature08562.PubMed CentralView ArticlePubMed
- Yu Z, Ji P, Cao J, Zhu S, Li Y, Zheng L, Chen X, Feng L: Dazl promotes germ cell differentiation from embryonic stem cells. J Mol Cell Biol. 2009, 1: 93-103. 10.1093/jmcb/mjp026.View ArticlePubMed
- Nicholas CR, Haston KM, Grewall AK: Transplantation directs oocyte maturation from embryonic stem cells and provides a therapeutic strategy for female infertility. Hum Mol Genet. 2009, 18: 4376-4389. 10.1093/hmg/ddp393.PubMed CentralView ArticlePubMed
- Rosner M, Dolznig H, Schipany K, Longacre TA, Reijo Pera RA: Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis. Oncotarget. 2011, 2: 705-712.PubMed CentralView ArticlePubMed
- De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY: Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 2007, 25: 100-106. 10.1038/nbt1274.View ArticlePubMed
- Stefanidis K, Loutradis D, Koumbi L, Anastasiadou V, Dinopoulou V, Kiapekou E, Lavdas AA, Mesogitis S, Antsaklis A: Deleted in Azoospermia-Like (DAZL) gene-expressing cells in human amniotic fluid: a new source for germ cells research?. Fertil. Steril. 2008, 90: 798-804. 10.1016/j.fertnstert.2007.06.106.View ArticlePubMed
- Cheng X, Chen S, Yu X, Zheng P, Wang H: BMP15 gene is activated during human amniotic fluid stem cell differentiation into oocyte-like cells. DNA Cell Biol. 2012, 31: 1198-1204. 10.1089/dna.2011.1396.View ArticlePubMed
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.View ArticlePubMed
- Liu T, Wu J, Huang Q, Hou Y, Jiang Z, Zang S, Guo L: Human amniotic epithelial cells ameliorate behavioral dysfunction and reduce infarct size in the rat middle cerebral artery occlusion model. Shock. 2008, 29: 603-611.View ArticlePubMed
- Zou K, Yuan Z, Yang Z, Luo H, Sun K, Zhou L, Xiang J, Shi L, Yu Q, Zhang Y, et al: Production of offspring from a germline stem cell line derived from neonatal ovaries. Nat Cell Biol. 2009, 11: 631-636. 10.1038/ncb1869.View ArticlePubMed
- Karlmark KR, Freilinger A, Marton E, Rosner M, Lubec G, Hengstschläger M: Activation of ectopic Oct-4 and Rex-1 promoters in human amniotic fluid cells. Int J Mol Med. 2005, 16: 987-992.PubMed
- Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M: Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research?. Hum Reprod. 2003, 18: 1489-1493. 10.1093/humrep/deg279.View ArticlePubMed
- Scholer H, Dressler G, Balling R, Rohdewohld H, Gruss P: Oct-4: a germ line specific transcription factor mapping to the mouse t-complex. EMBO J. 1990, 9: 2185-2195.PubMed CentralPubMed
- Pesce M, Wang X, Wolgemuth DJ, Scholer H: Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. Mech Dev. 1998, 71: 89-98. 10.1016/S0925-4773(98)00002-1.View ArticlePubMed
- Gupta SK, Jethanandani P, Afzalpurkar A, Kaul R, Santhanam R: Prospects of zona pellucida glycoproteins as immunogens for contraceptive vaccine. Hum Reprod Update. 1997, 3: 311-324. 10.1093/humupd/3.4.311.View ArticlePubMed
- Siegel N, Rosner M, Hanneder M, Valli A, Hengstschläger M: Stem cells in amniotic fluid as new tools to study human genetic diseases. Stem Cell Rev. 2007, 3: 256-264. 10.1007/s12015-007-9003-z.View ArticlePubMed
- Valli A, Rosner M, Fuchs C, Siegel N, Bishop CE, Dolznig H, Mädel U, Feichtinger W, Atala A, Hengstschläger M: Embryoid body formation of human amniotic fluid stem cells depends on mTOR. Oncogene. 2010, 29: 966-977. 10.1038/onc.2009.405.View ArticlePubMed
- Shiromizu K, Thorgeirsson SS, Mattison DR: Effect of cyclophosphamide. on oocyte and follicle number in Sprague–Dawley rats, C57BL/6N and DBA/2N mice. Pediatr Pharmacol. 1984, 4: 213-221.
- Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL: Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004, 428: 145-150. 10.1038/nature02316.View ArticlePubMed
- Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, Aebischer P, Svendsen CN: GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther. 2005, 16 (4): 509-521. 10.1089/hum.2005.16.509.View ArticlePubMed
- Misrahi M, Beau I, Meduri G, Bouvattier C, Atger M, Loosfelt H, Ghinea N, Hai MV, Bougnères PF, Milgrom E: Gonadotropin receptors and the control of gonadal steroidogenesis: physiology and pathology. Baillieres Clin Endocrinol Metab. 1998, 12 (1): 35-66. 10.1016/S0950-351X(98)80444-8.View ArticlePubMed
- Visser JA, de Jong FH, Laven JS, Themmen AP: Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006, 131: 1-9. 10.1530/rep.1.00529.View ArticlePubMed
- PS I t’A, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FHJ, Willemze R, Fibbe WE, Kanhai HHH: Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003, 102: 1548-1549. 10.1182/blood-2003-04-1291.View Article
- Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, Cho DJ, Kang SG, You J: Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif. 2007, 40: 75-90.View ArticlePubMed
- Bossolasco P, Montemurro T, Cova L, Zangrossi S, Calzarossa C, Miatiotis S, Soligo D, Bosari S, Silani V, Deliliers GL: Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Res. 2006, 16: 329-336. 10.1038/sj.cr.7310043.View ArticlePubMed
- Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ: Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod. 2006, 74: 545-551. 10.1095/biolreprod.105.046029.View ArticlePubMed
- Tanikawa M, Harada T, Ito M, Enatsu A, Iwabe T, Terakawa N: Presence of stem cell factor in follicular fluid and its expression in the human ovary. Fertil Steril. 2000, 73: 1259-1260. 10.1016/S0015-0282(00)00528-8.View ArticlePubMed
- Jeppesen JV, Nielsen ME, Kristensen SG, Yding Andersen C: Concentration of activin A and follistatin in follicular fluid from human small antral follicles associated to gene expression of the corresponding granulosa cells. Mol Cell Endocrinol. 2011, 356: 48-54.View ArticlePubMed
- Bruckova L, Soukup T, Visek B, Moos J, Moosova M, Pavelkova J, Rezabek K, Kucerova L, Micuda S, Brcakova E, et al: Proliferative potential and phenotypic analysis of long-term cultivated human granulosa cells initiated by addition of follicular fluid. J Assist Reprod Genet. 2011, 28: 939-950. 10.1007/s10815-011-9617-6.PubMed CentralView ArticlePubMed
- Angelucci S, Ciavardelli D, Di Giuseppe F, Eleuterio E, Sulpizio M, Tiboni GM, Giampietro F, Palumbo P, Di Ilio C: Proteome analysis of human follicular fluid. Biochimica et Biophysica Acta. 2006, 1764: 1775-1785. 10.1016/j.bbapap.2006.09.001.View ArticlePubMed
- Dyce PW, Wen L, Li J: In vitro germline potential of stem cells derived from fetal porcine skin. Nat Cell Biol. 2006, 8: 384-890. 10.1038/ncb1388.View ArticlePubMed
- Jiang JY, Cheung CK, Wang Y, Tsang BK: Regulation of cell death and cell survival gene expression during ovarian follicular development and atresia. Front Biosci. 2003, 8: d222-d237. 10.2741/949.View ArticlePubMed
- Webb R, Nicholas B, Gong JG, Campbell BK, Gutierrez CG, Garverick HA, Armstrong DG: Mechanisms regulating follicular development and selection of the dominant follicle. Reprod. 2003, 61: 71-90.
- Kee K, Gonsalves JM, Clark AT, Reijo Pera RA: Bone morphogenetic proteins induce germ cell differentiation from human embryonic stem cells. Stem Cells Dev. 2006, 15: 831-837. 10.1089/scd.2006.15.831.View ArticlePubMed
- West FD, Machacek DW, Boyd NL, Pandiyan K, Robbins KR, Stice SL: Enrichment and differentiation of human germ-like cells mediated by feeder cells and basic fibroblast growth factor signaling. Stem Cells. 2008, 26: 2768-2776. 10.1634/stemcells.2008-0124.View ArticlePubMed
- Tilgner K, Atkinson SP, Golebiewska A, Stojkovic M, Lako M, Armstrong L: Isolation of primordial germ cells from differentiating human embryonic stem cells. Stem Cells. 2008, 26: 3075-3085. 10.1634/stemcells.2008-0289.View ArticlePubMed
- Bucay N, Yebra M, Cirulli V, Afrikanova I, Kaido T, Hayek A, Montgomery AM: A novel approach for the derivation of putative primordial germ cells and Sertoli cells from human embryonic stem cells. Stem Cells. 2009, 27: 68-77. 10.1634/stemcells.2007-1018.View ArticlePubMed
- Park TS, Galic Z, Conway AE, Lindgren A, van Handel BJ, Magnusson M, Richter L, Teitell MA, Mikkola HK, Lowry WE: Derivation of primordial germ cells from human embryonic and induced pluripotent stem cells is significantly improved by coculture with human fetal gonadal cells. Stem Cells. 2009, 27: 783-795. 10.1002/stem.13.PubMed CentralView ArticlePubMed
- Visser JA, Schipper I, Laven JS, Themmen AP: Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012, 8 (6): 331-341.PubMed
- Bonilla-Musoles F, Castillo JC, Caballero O, Pérez-Panades J, Bonilla F, Dolz M, Osborne N: Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure. Clin Exp Obstet Gynecol. 2012, 39 (1): 13-18.PubMed
- Nygren JM, Jovinge S, BreitbachL M, Säwén P, Röll W, Hescheler J, Taneera J, Fleischmann BK, Jacobsen SE: Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004, 10: 494-501. 10.1038/nm1040.View ArticlePubMed
- Chavakis E, Urbich C, Dimmeler S: Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol. 2008, 45: 514-522. 10.1016/j.yjmcc.2008.01.004.View ArticlePubMed
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Embryonic stem cell lines derived from human blastocysts. Science. 1998, 282: 1145-1147.View ArticlePubMed
- Zhao T, Zhang ZN, Rong Z, Xu Y: Immunogenicity of induced pluripotent stem cells. Nature. 2011, 474: 212-215. 10.1038/nature10135.View ArticlePubMed
- Sessarego N, Parodi A, Podestà M, Benvenuto F, Mogni M, Raviolo V, Lituania M, Kunkl A, Ferlazzo G, Bricarelli FD: Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica. 2008, 93: 339-346. 10.3324/haematol.11869.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.